Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer

  • Technology appraisal guidance
  • TA263
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group (LRiG):

  • Fleeman N, et al, Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer, February 2012

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to give their expert views. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Manufacturer/sponsor:

  • Roche

II. Professional/specialist and patient/carer groups:

  • Breakthrough Breast Cancer

  • Breast Cancer Campaign

  • Macmillan Cancer Support

  • Cancer Research UK

  • Royal College of Nursing

  • Royal College of Physicians

III. Other consultees:

  • Department of Health

  • Welsh Government

IV. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services, and Public Safety, Northern Ireland

  • Healthcare Improvement Scotland

  • Liverpool Reviews and Implementation Group (LRiG)

  • National Institute for Health Research, Health Technology Assessment Programme

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer/sponsor consultees and commentators. They gave their expert personal view on bevacizumab by attending the Committee discussion and providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Rachel Greig, nominated by Breakthrough Breast Cancer – patient expert (attended first Committee discussion)

  • Dr Helena Earl, Consultant Medical Oncologist, nominated by Royal College of Physicians– clinical specialist (written comments submitted for first Committee discussion, attended second Committee discussion)

D. Representatives from the following manufacturer/sponsor attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Roche